1. Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer
   茜 吴, 2020, Advances in Clinical Medicine CrossRef
2. Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
   Qiaoping Xu et al, 2021, Cost Effectiveness and Resource Allocation CrossRef
3. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
   Megan Jagosky et al, 2021, Breast Cancer: Targets and Therapy CrossRef
4. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis
   Nurul Wafiqah Saipol Bahrin et al, 2024, Systematic Reviews CrossRef
5. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
   Isabel Echavarria et al, 2017, Breast Cancer Research and Treatment CrossRef
6. Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer
   Qingchang Su et al, 2023, Scientific Reports CrossRef
7. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience
   A Gogia et al, 2017, Indian Journal of Cancer CrossRef
8. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis
   Juan Bayo et al, 2018, The Breast Journal CrossRef
9. A Study of Hormone Receptor Status in Breast Carcinoma and use of HER2-Targeted Therapy in a Tertiary Care Center of India
   Sandeep Bhaskar et al, 2019, Indian Journal of Medical and Paediatric Oncology CrossRef